Silverfin false false 31/08/2024 01/09/2023 31/08/2024 Mr G J Remfry 11/11/2019 Mrs E Remfry 08/02/2022 30 January 2025 The principal activity of the Company during the financial year is provision of human wellness and health activities. 12307768 2024-08-31 12307768 bus:Director1 2024-08-31 12307768 bus:Director2 2024-08-31 12307768 2023-08-31 12307768 core:CurrentFinancialInstruments 2024-08-31 12307768 core:CurrentFinancialInstruments 2023-08-31 12307768 core:ShareCapital 2024-08-31 12307768 core:ShareCapital 2023-08-31 12307768 core:RetainedEarningsAccumulatedLosses 2024-08-31 12307768 core:RetainedEarningsAccumulatedLosses 2023-08-31 12307768 core:OfficeEquipment 2023-08-31 12307768 core:OfficeEquipment 2024-08-31 12307768 bus:OrdinaryShareClass1 2024-08-31 12307768 2023-09-01 2024-08-31 12307768 bus:FilletedAccounts 2023-09-01 2024-08-31 12307768 bus:SmallEntities 2023-09-01 2024-08-31 12307768 bus:AuditExemptWithAccountantsReport 2023-09-01 2024-08-31 12307768 bus:PrivateLimitedCompanyLtd 2023-09-01 2024-08-31 12307768 bus:Director1 2023-09-01 2024-08-31 12307768 bus:Director2 2023-09-01 2024-08-31 12307768 core:OfficeEquipment core:TopRangeValue 2023-09-01 2024-08-31 12307768 2022-09-01 2023-08-31 12307768 core:OfficeEquipment 2023-09-01 2024-08-31 12307768 bus:OrdinaryShareClass1 2023-09-01 2024-08-31 12307768 bus:OrdinaryShareClass1 2022-09-01 2023-08-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 12307768 (England and Wales)

THRIVEBIOMEDICA LIMITED

Unaudited Financial Statements
For the financial year ended 31 August 2024
Pages for filing with the registrar

THRIVEBIOMEDICA LIMITED

Unaudited Financial Statements

For the financial year ended 31 August 2024

Contents

THRIVEBIOMEDICA LIMITED

BALANCE SHEET

As at 31 August 2024
THRIVEBIOMEDICA LIMITED

BALANCE SHEET (continued)

As at 31 August 2024
Note 2024 2023
£ £
Fixed assets
Tangible assets 3 808 0
808 0
Current assets
Stocks 4 0 6,000
Debtors 5 33,829 5,463
Cash at bank and in hand 5,056 7,569
38,885 19,032
Creditors: amounts falling due within one year 6 ( 32,972) ( 17,495)
Net current assets 5,913 1,537
Total assets less current liabilities 6,721 1,537
Net assets 6,721 1,537
Capital and reserves
Called-up share capital 7 1 1
Profit and loss account 6,720 1,536
Total shareholders' funds 6,721 1,537

For the financial year ending 31 August 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Thrivebiomedica Limited (registered number: 12307768) were approved and authorised for issue by the Board of Directors on 30 January 2025. They were signed on its behalf by:

Mr G J Remfry
Director
THRIVEBIOMEDICA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 August 2024
THRIVEBIOMEDICA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 August 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Thrivebiomedica Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 44 Buckingham Road, Shoreham-By-Sea, BN43 5UD, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer.
Revenue from services is recognised as they are delivered.

Taxation

Current tax
Current tax is provided at amounts expected to be paid using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a basis over its expected useful life, as follows:

Office equipment 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 2 2

3. Tangible assets

Office equipment Total
£ £
Cost
At 01 September 2023 1,000 1,000
Additions 868 868
At 31 August 2024 1,868 1,868
Accumulated depreciation
At 01 September 2023 1,000 1,000
Charge for the financial year 60 60
At 31 August 2024 1,060 1,060
Net book value
At 31 August 2024 808 808
At 31 August 2023 0 0

4. Stocks

2024 2023
£ £
Work in progress 0 6,000

5. Debtors

2024 2023
£ £
Other debtors 33,829 5,463

6. Creditors: amounts falling due within one year

2024 2023
£ £
Corporation tax 27,922 15,123
Other taxation and social security 3,250 1,052
Other creditors 1,800 1,320
32,972 17,495

7. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
2 Ordinary shares of £ 0.50 each 1 1

8. Related party transactions

Transactions with owners holding a participating interest in the entity

2024 2023
£ £
Key management 33,829 5,262

Interest has been charged on the directors loan account as per HMRC rates.